Novartis picks up FDA approval for targeted lung cancer meds Tafinlar, Mekinist
Fierce Pharma -------- Patients in the U.S. with a specific lung cancer will soon have their first targeted treatment option with Novartis’ FDA approval for Tafinlar plus Mekinist. U.S. drug regulators signed off on the combo to treat metastatic non-small cell lung cancer (NSCLC) with the BRAF V600E mutation on Thursday based on phase 2 study results showing that more than 60% of treatment-naive and previously treated patients responded to the treatment. BRAF mutations occur in about 1% to 3% of NSCLC cases around the world, according to Novartis, while BRAF V600E tumors are aggressive and leave patients with a poor prognosis. To learn more click on the picture below to read the article.